Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | XPO1 | O14980 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096954 | 1.00 | TTR (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL457578 | 0.85 | TTR (0.49) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL457579 | 0.85 | TTR (0.49) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL29302292 | 0.84 | TTR (0.43) | TTRCA12CA1CA2CA7 | |
| SCHEMBL29136981 | 0.84 | TTR (0.43) | TTRCA12CA1CA2CA7 | |
| SCHEMBL17054008 | 0.83 | TTR (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL22186887 | 0.83 | TTR (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL29403887 | 0.83 | TTR (0.47) | TTRDPP4CA12CA1CA2 | |
| SCHEMBL4082454 | 0.80 | XPO1 (0.46) | MAPTALDH1A1CYP3A4L3MBTL1XPO1 | |
| SCHEMBL16126124 | 0.80 | CA12 (0.47) | TTRDPP4CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1897880-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029975-A1 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF | MIF, CCL2, MSR1 | TTR 3788/4885DPP4 1738/4885CA12 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.